MyFinsight
Home
Blog
About
Contact
Download
Download image
Cash and cash
equivalents
$229,342K
Marketable securities
$70,872K
Prepaid expenses and
other current assets
$7,712K
Research and development
tax credit...
$6,200K
Inventory
$3,428K
Accounts receivable, net
$2,593K
Total current assets
$320,147K
Right of use assets
$9,825K
Property and equipment,
net
$3,034K
Other assets
$2,369K
Total assets
$335,375K
Accumulated deficit
-$762,694K
Accumulated other
comprehensive loss
-$7,129K
Total liabilities and
stockholders' (deficit)...
$335,375K
Total stockholders'
(deficit) equity
-$2,711K
Additional paid-in capital
$767,061K
Common stock, 0.001 par
value 100,000,000...
$51K
Total liabilities
$338,086K
Convertible notes
$139,227K
Royalty obligation - net
of current portion
$119,063K
Total current
liabilities
$57,355K
Deferred revenue - net of
current portion
$11,714K
Lease liability - net
of current portion
$10,727K
Accrued expenses and
other current...
$33,897K
Royalty obligation -
current portion
$13,569K
Accounts payable
$8,268K
Lease liability -
current portion
$1,621K
Back
Back
Balance Sheet
source: myfinsight.com
KalVista Pharmaceuticals, Inc. (KALV)
KalVista Pharmaceuticals, Inc. (KALV)